Try our Advanced Search for more refined results
Health
-
April 01, 2026
Feds Can't Block Calif. Law Banning New Drilling Near Homes
A California federal judge has refused to block enforcement of a California statute banning new fossil fuel development within 3,200 feet of homes and schools, ruling the U.S. government failed to show the statute conflicts with federal law since it limits environmental emission impacts and "arguably furthers federal objectives."
-
April 01, 2026
DC Cannabis Co. Sues Firm Over Botched Grow Facility
A cannabis industry-focused engineering firm reneged on a promise to build a fully operational indoor grow facility for a D.C.-based medical dispensary, the company told a D.C. federal court, claiming it is now stuck with the unfinished project and $1 million in specialized equipment that can't be resold.
-
April 01, 2026
DOL, HHS Must Face Unions' Claims In DOGE Data Suit
The U.S. Departments of Labor and Health and Human Services must continue facing claims that they illegally gave Elon Musk's Department of Government Efficiency access to employee records, as a D.C. federal judge denied the agencies' bid to escape the union-brought allegations before the trial phase.
-
April 01, 2026
NJ Hospital Workers Win Collective Cert. In OT, Break Suit
A New Jersey healthcare network must face overtime claims on a collective basis, a federal judge ruled, saying a former employee adequately backed up allegations that the network had companywide policies under which it automatically deducted time for meal breaks that weren't taken and left bonuses out of overtime calculations.
-
April 01, 2026
Sentara Health Strikes $1.5M Deal In Stable Value Fund Suit
Virginia-based healthcare system Sentara Health will pay $1.5 million to settle a class action claiming it failed to remove an underperforming investment fund from its employee retirement plan, according to federal court filings.
-
April 01, 2026
Mass. Cannabis Businesses Say Repeal Bid Misleads Voters
A coalition of Massachusetts cannabis business owners Wednesday challenged the constitutionality of a proposal to repeal retail marijuana legalization at the ballot box this November.
-
April 01, 2026
PBM Opioid Crisis Suit Stays In Federal Court, Judge Says
A Michigan federal judge on Tuesday denied a request from the state attorney general to remand to state court a suit accusing two pharmacy benefit managers of fueling the opioid crisis, saying the case will remain in federal court because work performed for federal and nonfederal clients cannot be separated.
-
April 01, 2026
CFO Scores $867K Win In Health Device Co. Wage Suit
A wearable health device company must pay its former chief financial officer nearly $867,000 after a Connecticut federal jury determined it stiffed him on his full wages and benefits, according to court filings.
-
April 01, 2026
Mangione's NY Trial Moved Hours After SDNY Schedule Tweak
A New York state court judge said Wednesday that Luigi Mangione's trial for the alleged murder of UnitedHealthcare CEO Brian Thompson would begin Sept. 8, moving the date hours after a Manhattan federal judge said the federal trial against him would commence in late October.
-
March 31, 2026
State Privacy Enforcers Broadening Work As Resources Grow
Privacy regulators from California, Connecticut and two other states said Tuesday that their behind-the-scenes enforcement work will soon yield public actions that focus not only on established topics such as consumer opt-outs and transparency, but also fresh issues like harms stemming from artificial intelligence and ensuring fines are more than just "a cost of doing business."
-
March 31, 2026
'Best Judicial System In The World': Alsup Reflects On Career
Before taking inactive status late last year, U.S. District Judge William H. Alsup presided over historic litigation in California's Northern District for 26 years, arriving at his San Francisco chambers every weekday before dawn to prepare for the day's work.
-
March 31, 2026
Split 4th Circ. Affirms Injunction On W.Va. Drug Discount Law
A split Fourth Circuit panel sided with a trio of pharmaceutical manufacturers Tuesday that opposed a West Virginia law addressing drug delivery in the 340B program, saying the law attempted to reshape the "contractual bargain" Congress makes with private parties through its spending powers.
-
March 31, 2026
Novartis Seeks To Block New Wash. 340B Drug-Pricing Law
Novartis has called on a Washington federal judge to block a new state law it claims illegally expands the subsidies manufacturers must pay under the federal government's 340B Drug Pricing Program, arguing drugmakers will lose millions of dollars annually if the law is allowed to take effect in June.
-
March 31, 2026
Novartis Can't Nix FCA Suit Alleging MS Drug Kickbacks
Novartis must face a False Claims Act suit alleging it improperly had doctors prescribe its multiple sclerosis drug, a New York federal judge said Monday, finding the relator plausibly pled scienter by bringing evidence that the company "kept meticulous track" of how many prescriptions doctors wrote for the drug.
-
March 31, 2026
5th Circ. Grills Fraudsters Over $158M Healthcare Scheme
A Fifth Circuit panel pushed back on two men's contention that their convictions in a $158 million healthcare scheme should get thrown out, asking Tuesday how the evidence the jury heard wasn't enough to uphold the convictions.
-
March 31, 2026
Anesthesia Parent Can't Duck Antitrust Suit, But Affiliate Can
The parent company of U.S. Anesthesia Partners Inc. remains in the crosshairs of a private antitrust suit accusing it of trying to monopolize Texas anesthesia services, while a federal judge dismissed for now claims against an affiliate that he said was too far removed from the alleged rollup strategy.
-
March 31, 2026
Goodwin-Led Whoop Raises $575M At $10B Valuation
Wearable technology company Whoop Inc. announced Tuesday that it hit a $10.1 billion valuation after wrapping its latest funding round led by Goodwin Procter LLP, securing $575 million in investor commitments.
-
March 31, 2026
Full Fed. Circ. Is Told Panel Defied EcoFactor In DePuy Case
DePuy Synthes is urging the full Federal Circuit to review a circuit panel's decision reviving patent infringement litigation against it, saying the panel majority undermined the court's en banc EcoFactor decision on when to admit expert testimony.
-
March 31, 2026
SEIU Arbitration Suit Strains Order, Hospital Says
A Service Employees International Union unit is stretching an arbitrator's finding that a hospital unfairly punished a worker who tested positive for cannabis use by seeking to restrict drug tests going forward, the hospital argued Tuesday in its bid to beat an Ohio federal suit.
-
March 31, 2026
Telemedicine Biz Can't Escape Investor Suit Over User Losses
A New York federal judge on Tuesday ruled Teladoc Health Inc. cannot escape an investor suit over its declining user base and increased advertising budget, saying the departure of its former chief executive in 2024 could indicate the company knew it was misleading shareholders about its financial state.
-
March 31, 2026
Ill. Panel Says No Error In Doc's Nerve Damage Suit Win
An Illinois state appeals court panel won't upset a jury verdict that cleared a gynecologist from claims alleging her medical negligence caused nerve damage during a long procedure, finding the trial court wasn't wrong in its evidentiary or jury decisions.
-
March 31, 2026
Big Insurers Must Face 'Repricing' Antitrust Claims
Major insurance companies including Aetna, Cigna, Humana and UnitedHealth must face claims they conspired to reduce reimbursements to healthcare providers, a Massachusetts federal judge ruled Monday, finding that the doctors' allegations could constitute antitrust violations.
-
March 31, 2026
Mich. Judge OKs Bias Training For Healthcare Workers
A Michigan judge has upheld a state requirement that healthcare professionals undergo implicit bias training to obtain or renew their licenses, finding the mandate was within the state licensing bureau's power.
-
March 31, 2026
Biogen Paying $5.6B For Apellis As 4 Firms Advise
Biogen Inc. said Tuesday that it has agreed to acquire Apellis Pharmaceuticals Inc. in a cash transaction valued at about $5.6 billion, with four law firms steering the transaction focused on key therapies for kidney and eye disorders.
-
March 31, 2026
Pot Opponents Seek To Block CMS Hemp Benefit Program
A coalition of anti-cannabis activists is suing federal health regulators to block a program designed to reimburse Medicare beneficiaries for the use of federally legal hemp products that have small amounts of THC.
Expert Analysis
-
Series
Judges On AI: How Judicial Use Informs Guardrails
U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.
-
Lessons From EdTech Provider's Data Breach Settlements
Education technology company Illuminate Education's recent settlements with three states and the Federal Trade Commission over state privacy law claims following a student data breach are some of the first of their kind, suggesting a shift in enforcement focus to how companies handle student data and highlighting the potential for coordinated enforcement actions, say attorneys at Wilson Sonsini.
-
Justices' Med Mal Ruling May Spur Huge Shift For Litigators
The U.S. Supreme Court’s recent decision in the medical malpractice suit Berk v. Choy, holding that a Florida procedural requirement does not apply to medical malpractice claims filed in federal court, is likely to encourage eligible parties to file claims in federal court, speed the adjudicatory process and create both opportunities and challenges for litigators, says Thomas Kroeger at Colson Hicks.
-
What US Cos. Must Know To Comply With Italy's AI Law
Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.
-
Key Sectors, Antitrust Risks In Pricing Algorithm Litigation
Algorithmic pricing lawsuits have proliferated in rental housing, hotels, health insurance and equipment rental industries, and companies should consider emerging risk factors when implementing business strategies this year, say attorneys at Hunton.
-
Ag Bill Wording Presents Existential Threat To Hemp Industry
A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.
-
Series
Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief
My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.
-
5 Drug Pricing Policy Developments To Watch In 2026
2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.
-
Prisoners' Access To Health Info Should Have No Bars
To safeguard against unnecessary deaths in custody, courts and policymakers should clarify that incarcerated individuals’ constitutional right to medical care also includes access to sufficient information about their medical conditions, lifting current restrictions that can lead to crucial information being withheld, says Jaehyun Oh at Jacob Fuchsberg Law.
-
Navigating The New Wave Of Voluntary Benefit ERISA Suits
Four recent complaints claiming that employees pay unreasonable premiums for voluntary benefit programs contribute to a trend in Employee Retirement Income Security Act class actions targeting employers and benefits consultants over such programs, increasing scrutiny of how the programs are selected, priced and administered, say attorneys at Holland & Knight.
-
Series
Law School's Missed Lessons: How To Start A Law Firm
Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.
-
Justices' Med Mal Ruling May Hurt Federal Anti-SLAPP Suits
The U.S. Supreme Court's recent decision in Berk v. Choy restricts the application of certain state laws in diversity actions in federal court — and while the ruling concerned affidavit requirements in medical malpractice suits, it may also affect the use of anti-SLAPP statutes in federal litigation, says Travis Chance at Brownstein Hyatt.
-
Regulatory Uncertainty Ahead For Organ Transplant System
Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.
-
Key False Claims Act Trends From The Last Year
The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.
-
Opinion
It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs
The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.